AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04496934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
Study NCT04496934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
Study NCT02195284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
Study NCT02195284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS/ACCUHALER
Description: Placebo inhaler with one blister strip containing lactose monohydrate.
Study NCT02195284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
Study NCT02195284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TURBUHALER
Description: Placebo inhaler containing lactose monohydrate.
Study NCT02970058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich Plasma
Description: The active group will receive Platelet-rich Plasma following spinal injection
Study NCT02970058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive saline as a placebo
Study NCT02943499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App/Training
Description: This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
Study NCT03260439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol
Description: Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
Study NCT03260439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
Study NCT06693219 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography to confirm the correct placement of a nasogastric tube in the stomach
Description: The sonographic examination consisted of three parts: neck scan, epigastric scan, and injection test using a mixture of 25 mL NaCl 0.9% and 25 mL room air through the nasogastric tube to detect dynamic fogging
Study NCT06693349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth
Description: this procedure was anticipated to give superior effects than other procedure used in this study
Study NCT00287053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: Divalproex sodium vs. placebo
Study NCT00287053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: divalproex sodium
Description: Divalproex sodium vs. placebo
Study NCT01013818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1029
Description: HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
Study NCT02373839 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of PlGF
Description: If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
Study NCT04929730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nephrology care bundle
Description: Nephrology care bundle
Study NCT02625311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery method using CR TKP
Description: Operation through minimal invasive surgery or standard open surgery
Study NCT02625311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery method using CR TKP
Description: Operation through minimal invasive surgery or standard open surgery
Study NCT03727139 — intervention group
Intervention type: DRUG
Intervention: Rasagiline
Description: Rasagiline Tablets
Study NCT02242734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours
Study NCT03150901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: no drug
Description: laboratory tests
Study NCT03937206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutriterraTM
Description: Nutriterra 1000mg
Study NCT03937206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Corn Oil 1000mg
Study NCT03937206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Oil 1000mg
Study NCT04123587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: discontinuation of Sulfonylureas
Description: 1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent
Study NCT03141580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)
Description: Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
Study NCT05204537 — intervention group
Intervention type: PROCEDURE
Intervention: Lung parenchyma resection
Description: Lung parenchyma removal
Study NCT05204537 — intervention group
Intervention type: PROCEDURE
Intervention: Empyemectomy
Description: Intrapleural cavity effusion removal, parietal pleura removal.
Study NCT03735706 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation dose reduction
Description: The radiation dose is is different between groups
Study NCT03735706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast media volume reduction
Description: Contrast media volume is different between groups
Study NCT03735706 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unenhanced slice
Description: One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
Study NCT03735706 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Unenhanced slice
Description: One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
Study NCT03735706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Weight
Description: A weighing scale is used to measure a patients body weight right before the scan.
Study NCT02943499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App/Training
Description: It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
Study NCT02943499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Study NCT02943499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Study NCT05601063 — intervention group
Intervention type: BEHAVIORAL
Intervention: Winterlight Speech Assessment
Description: Digital assessment of speech and language abilities
Study NCT04029662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valsalva Maneuver
Description: Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
Study NCT02105012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 320 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Study NCT02105012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 160 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Study NCT02105012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 80 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Study NCT03735706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Weight
Description: A weighing scale is used to measure a patients body weight right before the scan.
Study NCT03708536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA >1.25 to \<1.50 m2), or 60 mg (BSA >1.50 m2).
Study NCT03708536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.
Study NCT03708536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
Study NCT03622229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Histologic evaluation
Description: Samples collected by EUS-FNB without ROSE will be processed as histologic samples
Study NCT03245333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
Study NCT02105012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 40 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Study NCT02105012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo MDI administered as 2 inhalations BID
Study NCT01993680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide
Description: Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days
Study NCT01993680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludrocortisone
Description: drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
Study NCT03844035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Periimplant crevicular fluid (PICF) collection
Description: Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
Study NCT03844035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periimplant crevicular fluid (PICF) collection
Description: Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
Study NCT04867629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rapeseed oil
Description: 20mL of rapeseed oil to be consumed daily in replacement to habitual oil
Study NCT04867629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sunflower oil
Description: 20mL of sunflower oil to be consumed daily in replacement to habitual oil
Study NCT02458027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hemp Shake
Description: Hemp Protein
Study NCT02458027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hemp
Description: Hemp Protein Shake
Study NCT02458027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Shake
Description: Soybean Protein
Study NCT02458027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soybean
Description: Soybean Protein Shake
Study NCT02458027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non-Protein Shake
Study NCT05815264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
Study NCT05815264 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal vaccine polyvalent
Description: This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
Study NCT02118415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hsp70-peptide TKD/IL-2 activated, autologous NK cells
Description: Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
Study NCT02957903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Study NCT02957903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Study NCT01903720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone implant
Description: OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
Study NCT03470883 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the long-term complete remission rate (> 12 months)
Description: Evaluation of the long-term complete remission rate (> 12 months)
Study NCT02006615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional near infrared spectroscopy
Description: Using high-sensitivity infrared to detect the active brain areas
Study NCT02006615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: To modulate brain cortex
Study NCT02006615 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: To modulate brain cortex
Study NCT01259531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
Study NCT04080531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM
Study NCT04080531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM
Study NCT04619849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EMG
Description: Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
Study NCT04619849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Palmaris Longus Test
Description: Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
Study NCT04205916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Drugs to be administer during cataract surgery to experimental group
Study NCT04205916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care surgery
Description: Standard method used for surgery and the use of post operative drops
Study NCT00309946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT02118831 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Collection
Description: Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
Study NCT02118831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: an intravitreal injection of Aflibercept administered three times on a monthly basis.
Study NCT02118831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: an intravitreal injection of Bevacizumab administered three times on a monthly basis.
Study NCT02118831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: an intravitreal injection of Ranibizumab administered three times on a monthly basis.
Study NCT04491110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
Study NCT04491110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: simulation with therapeutic education
Description: Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
Study NCT02096887 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Education
Description: Patient Education using the following two instruments:~1. Framingham Risk Score calculator:~2. Know your numbers patient booklet
Study NCT02934217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Cyclosporin
Description: one single intravenous bolus injection of 2.5 mg/Kg
Study NCT02934217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single intravenous bolus injection of Placebo
Study NCT02934217 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: 3 years after AMI
Study NCT02934217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: 3 years after AMI
Study NCT01366274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective manual hyperinflation
Description: Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
Study NCT01366274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual method of MHI
Description: Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
Study NCT03232892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2mg, once daily, PO, 28-day cycles